within Pharmacolibrary.Drugs.ATC.J;

model J05AJ01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.32,
    Cl             = 0.000325,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.082,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 19.8,            
    Vdp             = 0.149,
    k12             = 12.8,
    k21             = 12.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AJ01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Raltegravir is an antiretroviral medication used for the treatment of human immunodeficiency virus (HIV) infection. It is classified as an HIV integrase inhibitor and is approved for use in both treatment-naive and treatment-experienced adults, adolescents, and children.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult volunteers and HIV-infected patients following oral administration.</p><h4>References</h4><ol><li><p>Scarsi, KK, et al., &amp; Fletcher, CV (2020). HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. <i>Drugs</i> 80(16) 1649–1676. DOI:<a href=\"https://doi.org/10.1007/s40265-020-01379-9\">10.1007/s40265-020-01379-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32860583/\">https://pubmed.ncbi.nlm.nih.gov/32860583</a></p></li><li><p>Lommerse, J, et al., &amp; Chain, A (2019). Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 8(9) 643–653. DOI:<a href=\"https://doi.org/10.1002/psp4.12443\">10.1002/psp4.12443</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31215170/\">https://pubmed.ncbi.nlm.nih.gov/31215170</a></p></li><li><p>Anderson, MS, et al., &amp; Iwamoto, M (2010). Effect of raltegravir on the pharmacokinetics of methadone. <i>Journal of clinical pharmacology</i> 50(12) 1461–1466. DOI:<a href=\"https://doi.org/10.1177/0091270009360981\">10.1177/0091270009360981</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20173085/\">https://pubmed.ncbi.nlm.nih.gov/20173085</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AJ01;
